People who have received the Sinovac vaccine can come over and take a look; it wants to take your vaccination money and engage in "hollow-style" Dividend.
Kexing Bio was listed in the United States in its early years, but was suspended for 6 years due to internal equity disputes. Now, due to its failure to submit financial reports, it has been issued a delisting notice by Nasdaq. However, under the shadow of delisting, Sinovac Biotech has announced a massive dividend plan, intending to distribute $7.5 billion, equivalent to 53 billion RMB. This dividend plan basically distributes all of Sinovac Biotech's profits. During the pandemic, Sinovac Biotech made a huge profit, with an annual sales revenue of 140 billion and a profit of over 50 billion. This money was earned by us Chinese, one injection at a time. Now, Sinovac Biotech is going to use this money to distribute dividends to foreign shareholders. In response to the delisting in the United States, Sinovac Biotech has initiated its listing on the Hong Kong Stock Exchange, planning to issue 15% of its total share capital in Hong Kong stocks, with the funds raised to be used for research and development, overseas expansion, and to supplement operational funds. While giving American shareholders "extraction-style" dividends, they are also financing in Hong Kong stocks. Seeing this kind of outrageous operation, I really want to curse!
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
People who have received the Sinovac vaccine can come over and take a look; it wants to take your vaccination money and engage in "hollow-style" Dividend.
Kexing Bio was listed in the United States in its early years, but was suspended for 6 years due to internal equity disputes. Now, due to its failure to submit financial reports, it has been issued a delisting notice by Nasdaq.
However, under the shadow of delisting, Sinovac Biotech has announced a massive dividend plan, intending to distribute $7.5 billion, equivalent to 53 billion RMB.
This dividend plan basically distributes all of Sinovac Biotech's profits.
During the pandemic, Sinovac Biotech made a huge profit, with an annual sales revenue of 140 billion and a profit of over 50 billion. This money was earned by us Chinese, one injection at a time.
Now, Sinovac Biotech is going to use this money to distribute dividends to foreign shareholders.
In response to the delisting in the United States, Sinovac Biotech has initiated its listing on the Hong Kong Stock Exchange, planning to issue 15% of its total share capital in Hong Kong stocks, with the funds raised to be used for research and development, overseas expansion, and to supplement operational funds.
While giving American shareholders "extraction-style" dividends, they are also financing in Hong Kong stocks. Seeing this kind of outrageous operation, I really want to curse!